pirfenidone has been researched along with Blood Pressure, High in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Li, H; Wang, Y; Wu, Y; Zhao, S | 1 |
| Aebischer, O; Benmachiche, M; Bonjour, T; Carrel, G; Castioni, J; Cosma-Rochat, M; Fournier, J; Gachoud, D; Gagliano, M; Giger, A; Greiser, J; Lamy, O; Méan, M; Mieville, A; Rouiller Larpin, N; Tusgul, S; Voruz, S; Wenger, N | 1 |
| Margaritopoulos, G | 1 |
| Hanatani, A; Iwao, H; Izumi, Y; Muro, T; Nakamura, Y; Shimada, K; Shiota, M; Yamashita, N; Yamazaki, T; Yoshiyama, M | 1 |
| Abramowitz, MK; Bauer, C; Hostetter, TH; Melamed, ML; Turner, JM | 1 |
| Brown, L; Fenning, A; Margolin, SB; Mirkovic, S; Seymour, AM; Strachan, A; Taylor, SM | 1 |
1 review(s) available for pirfenidone and Blood Pressure, High
| Article | Year |
|---|---|
Treatment of chronic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Diabetes Mellitus, Type 2; Disease Progression; Endothelin-1; Humans; Hypertension; Kidney Failure, Chronic; Oleanolic Acid; Pyridones; Renal Insufficiency, Chronic; Renin-Angiotensin System | 2012 |
5 other study(ies) available for pirfenidone and Blood Pressure, High
| Article | Year |
|---|---|
Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrier Proteins; Collagen; Constriction; Fibrosis; Heart Ventricles; Hypertension; Hypertrophy, Left Ventricular; Interleukin-1beta; Male; Mice; Mice, Inbred BALB C; Myocarditis; Myocardium; Myocytes, Cardiac; Myofibroblasts; NLR Family, Pyrin Domain-Containing 3 Protein; Pyridones; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; Survival Rate; Transforming Growth Factor beta1; Ventricular Remodeling | 2013 |
[What is new in 2014 for the specialist in hospital internal medicine? The point of view of university hospital chief residents].
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arterial Pressure; Catheterization, Central Venous; Diverticulitis; Emergency Service, Hospital; Hospitals, University; Humans; Hypertension; Idiopathic Pulmonary Fibrosis; Internal Medicine; Kidney; Medical Staff, Hospital; Pneumonia; Pulmonary Embolism; Pyridones; Shock, Septic; Sympathectomy; Tumor Necrosis Factor-alpha; Ultrasonography; Venous Thromboembolism; Vitamin B 12 Deficiency; Vitamin E | 2015 |
Challenges in IPF diagnosis, current management and future perspectives: Patient case 2.
Topics: Adrenal Cortex Hormones; Aged; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Eruptions; Follow-Up Studies; Hemoptysis; Humans; Hypertension; Idiopathic Pulmonary Fibrosis; Male; Pyridones; Risk Assessment; Severity of Illness Index; Tachycardia, Supraventricular; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice.
Topics: Angiotensin II; Animals; Blood Pressure; Body Weight; Cardiomegaly; Fibrosis; Heart; Heart Rate; Hypertension; Male; Mice; Mice, Inbred BALB C; Myocardium; Pyridones | 2012 |
Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats.
Topics: Amiloride; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; Biological Availability; Collagen; Desoxycorticosterone; Fibrosis; Hypertension; Hypertrophy, Left Ventricular; Muscle Contraction; Muscle, Smooth, Vascular; Myocardial Contraction; Myocardium; Norepinephrine; Pyridones; Rats; Rats, Wistar; Sodium Chloride, Dietary; Vasoconstrictor Agents | 2002 |